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Abstract
Background: Responsiveness of the “jaundiced heart” to propofol is not completely understood. The purpose of
this study was to evaluate the effect of propofol on myocardial performance in rats with obstructive jaundice.
Methods: Male Sprague-Dawley rats (n = 40) were randomly allocated into two groups, twenty underwent bile duct
ligation (BDL), and 20 underwent a sham operation. Seven days after the surgery, propofol was administered in vivo
and ex vivo (Langendorff preparations). Heart rate, left ventricular end-systolic pressure (LVESP) left ventricular end-
diastolic pressure (LVEDP), and maximal rate for left ventricular pressure rise and decline (± dP/dtmax )w e r em e a s u r e d
to determine the influence of propofol on the cardiac function of rats.
Results: Impaired basal cardiac function was observed in the isolated BDL hearts, whereas in vivo indices of basal
cardiac function (LVESP and ± dP/dt) in vivo were significantly higher in rats that underwent BDL compared with
controls. With low or intermediate concentrations of propofol, these indices of cardiac function were within the
normal physiologic range in both groups, and responsiveness to propofol was unaffected by BDL. When the
highest concentration of propofol was administrated, a significant decline in cardiac function was observed in the
BDL group.
Conclusions: In rats that underwent BDL, basal cardiac performance was better in vivo and worse ex vivo
compared with controls. Low and intermediate concentrations of propofol did not appear to impair cardiac
function in rats with obstructive jaundice.
Background
Postoperative obstructive jaundice is associated with
multiple organ dysfunction syndrome [1-3]. Specifically,
the cardiovascular instability caused by defects in myo-
cardial performance and vascular reactivity is thought to
be an important mechanism in the pathophysiology of
multiple organ dysfunction syndrome [4,5]. In 1986,
Green [5] reported impaired left ventricular performance
in dogs with cholemia, and called this hepatic cardiomyo-
pathy “jaundiced heart”[4]. The jaundiced heart is also
characterized by defective vascular reactivity attributed to
altered beta-adrenergic receptor signaling [6], membrane
fluidity, and down regulation of cardiac beta-adrenocep-
tor density and affinity [7].
Propofol is a widely employed intravenous anesthetic
used to induce and maintain anesthesia. It is characterized
by rapid onset/offset of effect and rapid elimination from
the body [8,9]. However, propofol can also induce cardio-
vascular depression, manifested primarily by decreased
arterial blood pressure [10] due to inhibition of the sympa-
thetic nervous system [11], a negative inotropic effect [12],
and reduced preload [13].
The effect of propofol on myocardial performance in
patients with obstructive jaundice is unclear. Therefore,
in the present study, 7-day bile duct ligation (BDL) was
used as a model of obstructive jaundice to evaluate the
effect of propofol on cardiac function in vivo. In ex vivo
experiments, the direct effects of propofol on the isolated
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any medium, provided the original work is properly cited.heart of BDL rats were assessed to exclude the vasodila-
tor effect of propofol and the associated neurohormonal
adaptation in vivo [14,15].
Methods
Animals
This study protocol was approved by the Institutional Ani-
mal Care and Use Committee at the Second Military Med-
ical University. Male Sprague-Dawley rats (250-300 g)
were housed in a temperature and humidity-controlled
environment with a 12-h light dark cycle. The rats
received unlimited access to water and food. Food was
removed from the cage 16 hours before initiating the
experiments.
Procedures
Forty rats were randomly allocated into two study groups:
20 underwent the BDL procedure, and 20 underwent a
sham operation (control), according to Lee [16]. Rats were
anesthetized with pentobarbital sodium (40 mg/kg by
intraperitoneal [i.p.] administration). After opening the
abdominal cavity, the bile duct was ligated at a point prox-
imal to the hilus and a point immediately distal to the
entry of the bile duct into the duodenum. The bile duct
was then severed between the ligatures. The sham opera-
tion was carried out in a similar manner, but did not
include ligating and severing the bile duct. Seven days
after the BDL and sham procedures, blood was obtained
to assess total bilirubin and alanine aminotransferase
levels.
In vivo experiment
For the in vivo experiments, all surgical procedures were
performed under sterile conditions. On the seventh post-
operative day, rats (BDL group, n = 10; sham-operated
control group, n = 10) were anesthetized with sodium
pentobarbital (40 mg/kg i.p.). After tracheotomy and tra-
cheal intubation, mechanical ventilation (room air at 60-
70 breaths/min) was provided with a Harvard Apparatus
Rodent Respirator (Harvard Apparatus, Boston, MA). A
heating pad was placed under the animal to keep the rec-
tal temperature at 36°C ± 1°C. A 1-cm midline incision
was made in the neck, and the right common carotid
artery was exposed. A polyethylene cannula was inserted
through the artery to the left ventricle. To monitor intra-
ventricular pressure, the cannula was connected to a
pressure transducer (RM6240B type; Chengdu Instru-
ment Corp., China). A cannula connected to a microinfu-
sion pump (Graseby 3500; Graseby Medical Ltd.,
Watford, UK) via a three-port switch was placed in the
left jugular vein for propofol administration. After a 30-
min stabilization period, rats received an intravenous
injection of propofol (Diprivan 2%, AstraZeneca UK Ltd
UK) The dose range used in our study encompassed the
50% effective dose for propofol as reported by Carmi-
chael et al. [17]. Doses of 300, 600 and 900 μg/kg per
minute of propofol were administered by infusion
(15 min each dose) to generate dose-response curves for
heart rate (HR), left ventricular end-systolic pressure
(LVESP), and maximal rate for left ventricular pressure
rise and declining (± dP/dtmax ). HR and cardiac function
indices were determined at the point of maximum
response for each propofol dose.
Ex vivo experiment
Langendorff heart preparation (ML870B2 AD Instruments
Ltd, Shanghai, China) was used to evaluate the effects of
propofol on cardiac performance. The rats (BDL group,
n = 10; sham-operated control group, n =1 0 )w e r e
anesthetized with sodium pentobarbital (40 mg/kg i.p.).
The heart was removed from the thoracic cavity and
placed in ice-cold Krebs-Henseleit bicarbonate buffer (pH
7.4) containing heparin sodium. The heart was rapidly
mounted on a Langendorff perfusion system via the aorta.
A cardiac catheter, with a latex saccule at the tip, was
inserted from a cut in the left auricle of the left atrium to
the left ventricle. The saccule was filled with water to
maintain the left ventricular end-diastolic pressure
(LVEDP) at 6 to 8 mmHg. The other end of the catheter
was connected to a pressure transducer (MLT844; Shang-
hai, China). The average surrounding pressure was 70 to
80 mmHg. The perfusion medium was a modified Krebs-
Henseleit bicarbonate buffer gassed with 95% O2 and 5%
CO2 at atmospheric pressure and maintained at 37.5°C.
The buffer was composed of 118 mmol/L NaCl, 4.7 mmol/
LK C l ,1 . 2m m o l / LK H 2 PO4,2 5m m o l / LN a H C O 3,
2.5 mmol/L CaCl2, 11.0 mmol/L glucose, 0.5 mmol/L
EDTA-Na2 and 1.2 mmol/L MgSO4. Recorded parameters
included HR, LVESP, LVEDP, (and ± dP/dtmax). Effects of
propofol (12.5, 25, and 50 μmol/L) were tested using a
method described by Jacob et al [18]. In rats that under-
went 3-day BDL, Jacob [18] showed impaired basal cardiac
contractility and reduced left intraventricular pressure
using two preparations of pithed rats and isolated function-
ing hearts. When the aortic flow and left ventricular pres-
sure were stabilized, data were acquired for 30 consecutive
seconds prior to drug testing. Each drug concentration was
tested for a period of 15 min.
Statistical methods
Data analysis was performed with Prism version 4.0
(GraphPad Software; San Diego, CA). Responses of cardiac
function to propofol are expressed as mean ± standard
error of the mean (SEM) relative to baseline values (per-
centage). Group results were compared by Student’s
unpaired t-test or the chi-square test. In vivo and ex vivo
myocardial performance data were compared by two-way
repeated measure analysis of variance (ANOVA) followed
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considered significant.
Results
Serum total bilirubin and alanine transaminase in the BDL
group were significantly higher than those in the sham-
operated control group (total bilirubin, 1.4 ± 0.2 vs
158.7 ± 10.8 mM/L, respectively; alanine transaminase,
28.1 ± 1.9 vs 150.0 ± 14.2 IU/L respectively)(P < 0.01).
In vivo cardiac function
The baseline contractility and lusitropy (LVESP and ±
dP/dtmax) of the BDL group were higher than those of
the sham-operated controls (P < 0.05), although LVEDP
did not differ significantly between the two study groups
(Table 1). Blood pressure decreased in the BDL group
after propofol administration but there was no significant
difference compared with blood pressure after the same
propofol concentrations in the control group. At an infu-
sion rate of 300 to 600 μg/kg per min, propofol decreased
H R ,L V E S P ,a n d±d P / d t max, but not LVEDP. The
decreases in HR, LVESP, and ± dP/dtmax were dose-
dependent in both experimental groups (Figure 1). At
900 μg/kg per min, the inhibitory effects of propofol on
cardiac performance were greater in the BDL group than
in the sham-operated control group (P < 0.05) (Figure 1).
Ex vivo cardiac function
At baseline, LVESP, ± dP/dt, LVEDP and HR were signif-
icantly lower in the BDL group than in the control group
(P < 0.05) (table 2). At 12.5 and 50 μmol/L, propofol sig-
nificantly decreased HR, LVESP, and ± dP/dtmax,b u t
increased LVEDP. The dose-dependent decrease in
response appeared to be more pronounced in the BDL
group, and this difference was significant at 50 μmol/L of
propofol (P < 0.01) (Figure 2).
Discussion
In the present study, we could not confirm impaired
cardiac performance in a rat model of obstructive jaun-
dice because the in vivo and ex vivo results were incon-
sistent. However, an important and novel finding is that
the inhibitory effects of propofol on myocardial function
were comparable in rats that underwent BDL and rats
that underwent the sham operation at low and
intermediate doses (12.5 and 25 μmol/L). At the highest
dose of propofol tested (50 μmol/L), stronger effects on
cardiac function were observed in rats with obstructive
jaundice.
A propofol concentration of 2 to 4 μM was clinically
relevant according to a previous study [19], and research-
ers proved that higher than > 10 μMp r o p o f o li nv i t r o
might cause cardiovascular depression [20]. To compare
the hemodynamic effects of propofol between cholestatic
rat hearts and controls, we use d relatively high concentra-
tions (12.5, 25, and 50 μmol/L) of propofol ex vivo because
propofol at < 10 μM did not suppress the KATP channel
or display a myocardial depression effect [21]. The present
study did not confirm our hypothesis that propofol
depresses myocardial performance in the jaundiced heart
compared with the normal, healthy heart. This finding
may be attributed to a number of factors. First, most ani-
mal and human studies have shown that propofol induces
dose-dependent cardiovascular depression. Furthermore,
clinically relevant concentrations of propofol do not signif-
icantly depress myocardial contractility and evidence sug-
gests that its pharmacological properties may be due in
part to enhanced sensitivity of the myofilaments to Ca
2+,
despite reduced uptake of Ca
2+ uptake into the sarcoplas-
mic reticulum [22,23]. Moreover, propofol is a cardiopro-
tective agent and may protect the myocardium from
injury such as that caused by ischemia-reperfusion [24,25].
Inhibition of the mitochondrial permeability transition
pore is a recently reported mechanism underlying the pro-
tective action of propofol on the myocardium [24,26]. In
addition, accumulation of bile acids is a causative factor
for jaundiced heart [5]. Bile acids exert negative chrono-
tropic and inotropic effects on the heart via mitochondrial
damage [12,27]. These factors especially the enhanced sen-
sitivity of the myofilaments to Ca
2+ and the inhibition of
the mitochondrial permeability transition pore, may pro-
tect against cardiovascular depression and account for the
minimal responsiveness of BDL-treated rats to low and
intermediate concentrations of propofol.
Another interesting observation was the opposite in
vivo and ex vivo results of basal cardiac contractility in
the BDL group. In the ex vivo experiments, hearts
from the BDL-treated rats exhibited impaired contrac-
tility and a reduction in the maximum pressure in the
left ventricle, whereas BDL-treated rats showed
Table 1 In vivo baseline heart rate and cardiac function in the BDL group and sham control group
HR (bpm) LVESP (mmHg) LVEDP (mmHg) +dP/dtmax (mmHg s
-1) -dP/dtmax (mmHg s
-1) ABP (mmHg)
SO 355.5 ± 12.7 110.1 ± 4.3 3.7 ± 0.4 2173.6 ± 82.3 1249.7 ± 92.6 105 ± 17
BDL 311.3 ± 16.7* 127.2 ± 6.4* 4.5 ± 0.5 3288.7 ± 112.3* 2512.8 ± 132.5* 109 ± 13
(n = 10 in each group)
Values are means ± SEM; n, sample size; SO, sham-operated; BDL, bile duct ligation; HR, heart rate; LVESP, left ventricular end-systolic pressure; LVEDP, left
ventricular end-diastolic pressure; ± dP/dtmax , maximal rate for left ventricular pressure rising and declining; ABP, arterial blood pressure.
* P < 0.05 vs sham controls.
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in vivo. The mechanism underlying this phenomenon
is unclear, but may involve neural or humoral adapta-
tions. Dabagh [28] reported increased concentrations
of norepinephrine and epinephrine during the develop-
ment of cholestasis. Poo [29] found elevated renin and
angiotensin II at 1 week after establishment of obstruc-
tive jaundice in rats. In our in vivo experiments,
increased LVSEP, +dP/dtmax and -dP/dtmax,w e r ea s s o -
ciated with myocardial contractility, suggesting up reg-
ulation of the sympathetic nervous system. In addition,
LVEDP which directly relates to the cardiac preload
might remain unchanged possibly not owing to the
depletion of body fluid in obstructive jaundice [30,31].
However, the lower heart rate may be caused in part
by accumulated bile acids, which impair cardiac func-
tion by affecting calcium uptake from the sarcoplasmic
reticulum [32,33]. Recent research has focused on the
overproduction of nitric oxide, which results in brady-
cardia after BDL [34,35]. Despite enhanced cardiac
contractility in vivo, our experiment showed that a
high dose of propofol produced stronger inhibition of
cardiac function in BDL-treated rats, unmasking latent
cardiac dysfunction. These results are consistent with
those of previous studies reporting that BDL-treated
rats show hemodynamic instability [5].
Figure 1 In vivo effect of propofol on heart rate and indices of cardiac contractility on day 7 in a rat model of obstructive jaundiced
and sham-operated controls. (A) Heart rates. (B) Left ventricular end-systolic pressure (LVESP); (C) Left ventricular end-diastolic pressure
(LVEDP); (D) Maximal rate for left ventricular pressure rise (+dT/dtmax ). (E) Maximal rate of left ventricular pressure declining (-dP/dtmax ). (F)
Arterial blood pressure. Results are expressed as mean ± SEM(n = 10). SO, sham-operated control; BDL, bile duct ligation; HR, heart rate; Abscissa,
propofol concentration; ordinate, percent change in a given variable compared with baseline; closed circle, sham-operated rat; open circle, BDL
rat. For each twitch parameter, original hemodynamic data from the experimental groups were compared by two-way ANOVA followed by the
Bonferroni test. * P < 0.05 vs sham-operated controls (same propofol concentration).
Table 2 Ex vivo baseline heart rate and cardiac function in the BDL group and the sham control group
HR (bpm) LVESP (mmHg) LVEDP (mmHg) +dP/dtmax (mmHg s-1) -dP/dtmax (mmHg s-1)
SO (n = 10) 254.5 ± 19.5 112.5 ± 6.9 4.8 ± 0.5 1469.2 ± 157.4 1117.5 ± 70.0
BDL (n = 10) 201.3 ± 13.5* 92.4 ± 5.4* 7.4 ± 0.3* 1146.0 ± 64.2* 954.3 ± 103.7*
Values are means ± SEM; n, sample size; SO, sham operated; BDL, bile duct ligation; HR, heart rate; LVESP, left ventricular end-systolic pressure; LVEDP, left
ventricular end-diastolic pressure; ± dP/dtmax , maximal rate for left ventricular pressure rising and declining.
* P < 0.05 vs sham controls.
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ventricular inotropism, three load-dependent indices of
left ventricular contractility (LVESP, LVEDP, and ± dP/
dtmax ) were used. It must be underscored that these
indices may also be influenced by left ventricular loading
conditions [36]. Load-independent indices of left ventri-
cular contractility, such as construction of pressure-
volume curves in both systole and diastole would greatly
enhance the validity and interpretation of our results. It
w o u l de n a b l em o r es p e c i f i cm e a s u r e m e n to ft h el e f t
ventricular performance independent of both loading
conditions and HR [37]. Thus, the data of our study
must be interpreted with caution when using propofol
at mild to intermediate doses in obstructive jaundice.
Conclusions
In conclusion, the present study demonstrates that
obstructive jaundice impairs cardiac function ex vivo
but enhances cardiac performance in vivo. Propofol
depresses cardiac parameters at low and intermediate
doses to a similar degree in BDL-treated and sham-
operated rats. However, at a high dose, propofol may
cause exaggerated cardiac depression in jaundiced rats.
Our study suggestes that propofol is a safe alternative
anesthetic agent in patients with obstructive jaundice
and normal cardiac function at low and intermediate
doses.
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